Long-term Safety Study for GSK573719 in Japanese

NCT ID: NCT01702363 Phase: PHASE3 Status: COMPLETED Enrollment: 131 Completion: 2013-12

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

GSK573719

Summary

The objective of this study is to evaluate the safety and tolerability of GSK573719 Inhalation Powder 125 mcg once-daily over 52 weeks in Japanese subjects with COPD.

Primary Outcome

Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) Throughout the Treatment Period

Source

ClinicalTrials.gov